This page uses content from Wikipedia and is licensed under CC BY-SA.

Donor-specific antibody

Antibody-mediated transplant rejection involves B cell and plasma cell activation resulting in the generation of donor-specific antibodies (DSA), which bind to HLA and/or non-HLA molecules on the endothelium.[1] Preformed donor–specific HLA antibodies resulting in hyperacute rejection were first detected in 1969 by the complement-dependent cytotoxicity crossmatch assay.[2][3] The presence of pre-formed and de novo (newly formed) DSA, specific to donor/recipient mismatches are major risk factors for antibody-mediated rejection,[4] which results in both acute and chronic transplant injury and is the primary cause of accelerated early and late allograft loss.[1] Almost a third of patients who are waitlisted for transplantation may have a degree of anti-HLA antibodies detected. The usual route for sensitisation towards HLA antigens occurs in three instances; pregnancy, post blood transfusion and prior transplantation. Preformed antibodies increase the chances of immunological failure of the allograft by causing positive crossmatches and, thereby, result in the exclusion of donors.[5] For sensitised patients, successful transplantation is possible by employing strategies such as desensitisation, paired exchange and acceptable mismatching.[6][7]

Panel reactive antibody

The degree of cytotoxicity is expressed as percentage PRA (panel reactive antibody). It is a tool that can be employed to approximate the risk of a given recipient of having a positive crossmatch. This is to a likely organ donor taken from a similar population. The limitations of this method are that PRA percent can be different numerically without a corresponding change in the type or amount of antibody. This largely depends on the cell panel used which are commercially produced and may not truly represent the population. HLA frequencies and racial differences need to be factored in but cannot be done. Moreover, significant false positive results can be produced due to non-HLA antibodies, autoantibodies and nonspecific IgM antibodies. Similarly, false negative results are possible as this is purely complement dependent that requires higher antibody titres to be activated.[8][9] The lack of a complement activation simply due to low titres allows a true antibody to be hidden.[10]

Cross-match test

Patel and Terasaki[2] in 1969 demonstrated the efficacy of complement-dependent lymphocytotoxic cross-match in defining immunologic risk in renal transplantation. This became the standard method, still used today, for graft allocation. With PRA that identifies several antibodies to a potential cluster of donors, the crossmatch will identify if a recipient had antibodies to a specific donor of interest. It became clear with time that it did not identify all preexisting donor-specific HLA antibodies (HLA-DSA). In recent years, techniques for detection of HLA antibodies have become more sensitive with the introduction of solid-phase assays, including ELISA.[11]

References

  1. ^ a b Lionaki S, Panagiotellis K, Iniotaki A, Boletis JN. Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation. Clin Dev Immunol. 2013; 2013:849835.
  2. ^ a b Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969; 280(14):735-9.
  3. ^ Stiller CR, Sinclair NR, Abrahams S, Ulan RA, Fung M, Wallace AC. Lymphocyte-dependent antibody and renal graft rejection.. Lancet. 1975; 1(7913):953-4.
  4. ^ Fu, Y.; Sun, Z.; Fuchs, E. J.; Wang, Y.; Shen, Z.-Y.; Maeda, H.; Lin, Q.; Warren, D. S.; Williams, G. M. (2014-08-19). "Successful Transplantation of Kidney Allografts in Sensitized Rats After Syngeneic Hematopoietic Stem Cell Transplantation and Fludarabine". American Journal of Transplantation. 14 (10): 2375–2383. doi:10.1111/ajt.12815. ISSN 1600-6135. PMID 25139564.
  5. ^ Tinckam KJ. Basic histocompatibility testing methods. In:Chandraker A, editor. Core concepts in renal transplantation. New York:Springer Science + Business Media, LLC; 2012.21–42.
  6. ^ Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6(2):346-51.
  7. ^ Gentry SE, Segev DL, Simmerling M, Montgomery RA. Expanding kidney paired donation through participation by compatible pairs. Am J Transplant. 2007; 7(10):2361-70.
  8. ^ Amos DB, Cohen I, Klein WJ Jr. Mechanisms of immunologic enhancement. Transplant Proc. 1970; 2(1):68-75.
  9. ^ Kerman RH, Kimball PM, Van Buren CT, Lewis RM, DeVera V, Baghdahsarian V, Heydari A, Kahan BD. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation. 1991; 51(2):316-20.
  10. ^ Gebel HM, Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation. 2000; 69(7):1370-4.
  11. ^ Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant. 2003; 3(12):1488-500.